immunity has been observed in many subjects with type 1 diabetes and AIT. It has been report ed that patients with type 1 diabetes and AIT have high levels of aCL antibodies as a marker of auto immune dysregulation.
5-8 It has also been sug gested that high levels of aCL antibodies might predict vascular complications in diabetic pa tients.
1,9,10 Anzai et al. 11 reported the presence of aCL antibodies in AKR/J mice with streptozocin induced diabetes. Subsequently, a few more stud ies have been conducted to show the positivity of aCL antibodies in children with type 1 diabe tes. However, there have been no studies eval uating aCL antibody positivity in children with AIT so far. 1, 5, [7] [8] [9] 12 A few studies provided conflicting results on the prevalence of aCL antibodies in adult subjects with AIT. 7, 8, 12 In 1994, Paggi et al. 8
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Prevalence of anticardiolipin antibodies in type 1 diabetes and auto immune thyroiditis used for measuring the HbA 1c levels of diabet ic children. Normal HbA 1c levels were defined as 4.5%-5.7%.
After providing the legal guardians and fami lies of children with relevant information, a writ ten informed consent was obtained for the study and aCL antibody determination. The study was approved by the Internal Review Board of the Ethics Committee.
The data were analyzed with the SPSS 11.5 pack age. The Pearson correlation analysis was used to determine whether there was a relation between the duration of disease and aCL antibody positiv ity. The oneway variance analysis (ANOVA) and χ 2 tests were used to compare the laboratory and clinical para meters between the groups. When ANOVA analysis resulted in a significant differ ence (P <0.05), the Bonferroni posthoc test was used to identify a group that accounts for statisti cal significance (P <0.0167 was considered statis tically significant [P <0.05/3 = 0.0167]). All data were expressed as mean ± standard deviation.
REsuLTs
In the AIT group, the prevalence of anti TgAb and antitPOAb positivity was sig nificantly higher than in subjects with type 1 diabetes or healthy subjects (P >0.05) (TAbLE) . The positivity rate of aCL antibodies was high er in patients with AIT compared with diabet ic or healthy subjects when low positive cutoff level was used (21.9%, 5.4%, 5.7% for aCL IgG and 21.9%, 6.8%, 5.7% for aCL IgM, respective ly, P <0.05) (TAbLE) . However, when we used a me dium/high cutoff level, no significant difference was found between the groups (12.5%, 2.7%, 2.8% for aCL IgG and 12.5%, 5.4%, 2.8% for aCL IgM, respectively, P >0.05) (TAbLE) .
The aCL antibody titers were statistically high er in AIT compared with diabetic or healthy sub jects (14.2 ±28.9, 7.2 ±16.6, 1.9 ±6.7 for aCL IgG [GPL/ml] and 13.3 ±35.3, 3.1 ±11.6, 1.9 ±9.3 for aCL IgM [MPL/ml], respectively [TAbLE] ). No cor relation was found between aCL IgG and IgM antibody positivity and the duration of dis ease (r = 0.153, r = 0.02 for type 1 diabetes and r = 0.001, r = 0.009 for AIT, respectively). Three diabetic patients developed microvascular com plications (microalbuminuria), but none of them showed aCL antibody positivity. dIsCussION aCL antibodies are typically known as the sero logical markers of APS, an auto immune disease characterized mainly by venous and/or ar terial thrombosis, thrombocytopenia, and compli cated pregnancies with recurrent miscarriage.
17,18
It has been reported that aCL antibody positivi ty may reach up to 50% in patients with system ic lupus erythematosus and 53% in patients with juvenile rheumatoid arthritis. 19, 20 As for aCL an tibodies in type 1 diabetes, only a few studies on small patient populations have been conduct ed so far. 1, 5, 6 It has been observed that aCL antibody lev els were higher in patients with recentonset reported a study in which 4 out of 5 subjects with Hashimoto's thyroiditis showed the presence of aCL antibodies. Diez et al. 12 found no significant difference in the prevalence of aCL antibodies be tween the patients with AIT and healthy subjects (control group).
We aimed to determine the prevalence and sig nificance of aCL antibodies in children with type 1 diabetes and, for the first time, with AIT.
PATIENTs ANd mEThOds
The study group included patients who were followed up in the Department of Pediatric Endocrinology of the Dokuz Eylul University (Izmir, Turkey) and Gazi University (Ankara, Turkey). There were 74 subjects with type 1 diabetes (mean age 12.91 ±4.2 years, 40 girls), 64 subjects with AIT (mean age 14.1 ±3.71 years, 60 girls), and 35 healthy subjects (mean age 12.78 ±3.32 years, 26 girls). The mean duration (minimum--maximum) of diabetes was 3.62 ±2.76 (0-13) and AIT was 2.51 ±2.19 (0.08-8) years. The mean HbA 1c value and mean insulin requirement were determined as 8.39 ±1.84% (5.4-17.4) and 1.3 ±0.4 IU/kg/day, respectively. The patients' med ical records were assessed (adverse reactions to drugs, history of immunosuppressive treatment or chronic disease) and their relatives examined (venous and/or arterial thrombosis/thrombotic microangiopathy, thrombocytopenia, recurrent fetal losses, infections, malignancies, and oth er auto immune diseases) to identify any addi tional medical problems. The subjects underwent thorough physical examination prior to the study. The diagnosis of type 1 diabetes was made based on the World Health Organization criteria and AIT was diagnosed on the basis of a history of typ ical symptoms or signs of hypothyroidism, includ ing high serum thyrotropin levels and the pres ence of either antithyroglobulin (antiTgAb) or antithyroid peroxidase (antitPOAb) antibodies (or both) in serum. 7, 13, 14 The control group com prised children without any infectious and auto immune diseases.
The serum levels of antiTgAb, antitPOAb, and aCL anti bodies were measured in all patients with type 1 diabetes and AIT regardless of disease du ration. The cutoff for a negative result has been defined as <10 IU/ml for both antitPOAb and antiTgAb.
aCL IgG and aCL IgM antibodies were mea sured with enzymelinked immunosorbent as say (ELISA) (ZEUS Lübeck, Germany). The re sults were inter preted using the following Sap poro criteria 15, 16 : low positive, aCL IgG and IgM levels of 20 GPL/ml and 20 MPL/ml, respective ly; medium/ high positive, aCL IgG and IgM levels above 40 GPL/ml/MPL/ml and 80 GPL/ml/MPL/ ml (>99th percentile), respectively.
The age at the time of diagnosis, the dura tion of diabetes, the doses of insulin according to weight, and the HbA 1c levels of patients with diabetes were determined. Cobra Integra 400 plus device (Roche Diagnostics, Shweiz) was These data raised the question whether aCL anti body positivity could be a predictor of lateonset micro and macrovascular complications. Howev er, longterm followup studies that evaluate pa tients with aCL antibody positivity are required to demonstrate such a relationship.
It has also been shown previously that aCL an tibody positivity was not associated with good meta bolic control in diabetic patients. 5 Howev er, Mohammed et al.
6 reported a positive corre lation between diabetes duration and aCL anti body titer. Such relationship was not confirmed in the current study.
So far, researchers have provided inconsistent data on the prevalence of aCL antibody positiv ity in AIT. 7, 8, 12 The cause of this prevalence still remains unknown.
7,11 However, it has been re ported that the positivity might be an unspe cific indicator of auto immune dysregulation. 7,8 Osundeko et al.
7 studied IgA, IgG, and IgM aCL antibodies in 19 patients with isolated AIT aged between 26 and 79 years and found the positiv ity rate of 21% (IgG in 2 and IgM in 2 cases). On the other hand, Diez et al. 12 determined aCL an tibody positivity in 10.1% (7/69) of AIT patients (Graves' disease and Hashimoto's thyroiditis). However, this rate was similar to that detect ed in nonAIT subjects (11.2%) and healthy sub jects (4.1%). Paggi et al. 8 reported that patients with uncontrolled and severe Graves' disease had high levels of aCL antibodies, which decreased af ter methimazole therapy.
8 In our study, the pres ence of both aCL IgG and IgM antibodies was de tected at the rate of 21.9% in the AIT group when low positive aCL cutoff level was used, which was higher than in other studies. Nevertheless, none of our patients had any symptoms or signs of APS and no correlation was found between the pres ence of antibodies and duration of AIT. A num ber of studies have suggested that the clinical diabetes. 6 GaltierDereure et al. 1 assessed the pre valence of aCL antibodies in diabetes with and without complications and found aCL antibod ies in 9.4% and 9.5% of type 1 and type 2 diabet ic patients, respectively. They also found a high er prevalence of these antibodies in diabetic pa tients with macroangiopathy (32.4%) or overt nephropathy (32.1%) and suggested a potential role of aCL antibodies in the progression of dia betic vascular complications. However, a high rate of aCL antibody positivity in patients with neph ropathy was not related to primary renal patholo gy. Mohamed et al. 6 demonstrated that the mean levels of serum aCL antibodies were significantly higher in subjects with type 1 diabetes, even in very young diabetics without complications, than in healthy subjects. In addition, they found a neg ative correlation between the duration of diabetes and aCL antibody levels. Lorino et al. 5 detected aCL IgG antibody positivity in 24% (7/29) of di abetic patients, while aCL IgM antibody positivi ty was not detected at all. Ahmed et al.
9 reported an increased prevalence of aCL IgM antibodies in diabetic adults with vascular complications, but not in patients without vascular complications and healthy subjects. In the same study, the prev alence of aCL IgG positivity was determined as 21% (8/38) in type 2 diabetes and 4.9% (5/102) in healthy subjects. The present study, in which no statistical significance was found between type 1 diabetes and healthy subjects regarding aCL antibody positivity, suggested that screen ing for aCL antibodies in diabetics has no clinical importance. Likewise, the positivity of certain an tibodies in diabetic patients does not always in dicate organ dysfunction. For example, the ma jority of diabetic patients with antithyroidal an tibody positivity do not experience hypothyroid ism. Therefore, aCL positivity does not determine the development of microvascular complications. features of APS are associated with high levels of IgG aCL and only about 30% of individuals with antiphospholipid antibodies develop the clinical syndrome. 7,21 Accordingly, when we used medi um/high cutoff levels, the frequency of antibody positivity was similar between the groups. All of these findings led us to consider that elevated aCL antibody levels in AIT are a nonspecific indicator of auto immune dysregulation. Our study has several limitations. First, the presence of aCL positivity in 2 or more sam ples obtained at least 12week inter vals is re quired to diagnose APS, 15 while we were able to perform only 1 aCL measurement and unable to study lupus anticoagulant or antibodies against β2glycoprotein 1. Second, aCL antibody may also be positive in some infectious diseases, such as syphilis, human immunodeficiency virus (HIV), and hepatitis C virus (HCV) infections. 18 Howev er, we did not investigate positivity for syphilis, HCV or HIV infection due to a lack of indications in medical history and clinical findings.
In conclusion, our study showed a high preva lence of aCL antibody positivity in patients with AIT at a lowpositive aCL cutoff level. However, at a medium/high aCL cutoff level, the rate of aCL antibody positivity between the groups was similar. In addition, the rate of positivity of aCL antibodies did not correlate with clinical findings in patients with AIT and type 1 diabetes. For all of these reasons, we believe that a routine inves tigation of aCL antibodies in childhood may not have a clinical significance for diabetic and AIT patients without vascular or clinical symptoms. However, studies with a longterm followup of these patients are needed to determine a possi ble association between aCL antibodies and vas cular complications that may develop in the lat er stages of the disease.
